dc.rights.license | CC-BY-NC-ND | |
dc.contributor.advisor | Externe beoordelaar - External assesor, | |
dc.contributor.author | Zweers, Berber | |
dc.date.accessioned | 2022-12-01T00:00:39Z | |
dc.date.available | 2022-12-01T00:00:39Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/43257 | |
dc.description.abstract | Introduction: The standard first-line treatment for diffuse large B-cel lymphoma (DLBCL), an aggressive non-hodgkin
lymphoma, is the R-CHOP regimen: a combination of rituximab, cyclophosphamide, doxorubicin, vincristine and
prednisone. The most common adverse effect of this regime is neurotoxicity caused by vincristine. For this reason
vincristine is frequently reduced or omitted from the therapy.
Methods: In this retrospective cohort study medical records from patients with de novo DLBCL, diagnosed between
2015 and 2021, were reviewed. The objective was to investigate the effect of vincristine dose reduction on overall
survival and progression free survival in DLBCL patients treated with R-CHOP. Patients were included if they had
completed at least six courses of chemotherapy. Survival status was obtained through the personal records database.
Results: In total 101 patients were included in our analysis. Vincristine was reduced or omitted in 49/101 patients. The overall survival of all patients was high, 88%. Vincristine reduction did not affect progression free survival or overall survival in our cohort. Relative dose intensity <85% produced a hazard ratio of 0.359 (95% confidence interval 0.097-1.325). In univariate analysis only age was associated with poorer survival.
Discussion: Even though our study was potentially underpowered, we did not find a difference in progression free
survival or in overall survival in DLBCL patients with and without reduction of vincristine from the R-CHOP regimen. | |
dc.description.sponsorship | Utrecht University | |
dc.language.iso | EN | |
dc.subject | Het effect van dosis reductie van vincristine in de R-CHOP kuur op de overleving werd retrospectief onderzocht bij patiënten die in opzet curatief werden behandeld voor een diffuus grootcellig B-cel lymfoom. | |
dc.title | Impact of vincristine dose reduction on overall survival in patients with DLBCL | |
dc.type.content | Master Thesis | |
dc.rights.accessrights | Open Access | |
dc.subject.keywords | DLBCL; Vincristine dose reduction; R-CHOP; overal survival | |
dc.subject.courseuu | Geneeskunde | |
dc.thesis.id | 3843 | |